Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07145489 · ClinicalTrials.gov registry record · NA

Infrared Photobiomodulation in Humans With Epilepsy

A NA study of Drug Resistant Epilepsy, sponsored by Beth Israel Deaconess Medical Center.

Recruiting
Registry status
NA
Development phase
13
Enrollment target
1
Study location

NCT07145489 is a NA study of Drug Resistant Epilepsy that is actively recruiting participants, run by Beth Israel Deaconess Medical Center. The registered enrollment target is 13 participants, below the 35-participant average among 6 other Drug Resistant Epilepsy trials with a reported enrollment target (63% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07145489, a NA study of Drug Resistant Epilepsy, is actively recruiting participants, sponsored by Beth Israel Deaconess Medical Center.

RECRUITING
Registry status
NA
Development phase
13 participants
Enrollment target
1
Study location

Study Summary

Drug-resistant epilepsy represents roughly 40% of people with epilepsy. It is very challenging to stop seizures in this condition, and the treatment options are limited. This study aims to investigate a new treatment that involves using infra-red light. In animals, this treatment has shown promise as a possible way to reduce seizures, but it has not been tested in humans for this. The investigators are interested to know if it can reduce seizures, and how comfortable it is to be treated with this therapy.

Conditions Studied

Interventions

  • DEVICE photobiomodulation

Study Locations (1)

Massachusetts

  • BIDMC - Boston

Trial Details

FieldValue
Enrollment Target 13 participants
Start Date 2025-11-25
Est. Completion 2027-09-25
Phase NA

What the Registry Record Tells You About NCT07145489

The ClinicalTrials.gov registry entry for NCT07145489 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 35-participant average among 6 other Drug Resistant Epilepsy trials with a reported enrollment target (63% lower). The listed sponsor is Beth Israel Deaconess Medical Center, which has 488 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Drug Resistant Epilepsy appearing as the primary indexed condition, and to 1 intervention - of which photobiomodulation is the first listed.

NCT07145489 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.

Frequently Asked Questions

What is clinical trial NCT07145489 about?

NCT07145489 is a clinical study titled "Infrared Photobiomodulation in Humans With Epilepsy". Drug-resistant epilepsy represents roughly 40% of people with epilepsy. It is very challenging to stop seizures in this condition, and the treatment options are limited. This study aims to investigate a new treatment that involves using infra-red light. In animals, this treatment has shown promise a...

What is the current status of trial NCT07145489?

This trial is currently recruiting. It is a NA study. The enrollment target is 13 participants. The study started on 2025-11-25. Estimated completion is 2027-09-25.

What conditions does trial NCT07145489 study?

This clinical trial studies the following conditions: Drug Resistant Epilepsy.

What interventions are being tested in trial NCT07145489?

The interventions under investigation include: photobiomodulation (DEVICE).

Who is sponsoring clinical trial NCT07145489?

This trial is sponsored by Beth Israel Deaconess Medical Center, which has 488 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07145489 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Drug Resistant Epilepsy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.